Antibody-mediated disruption of Nrp2/VEGF-C has been found to reduce tumor lymphangiogenesis of murine mammary carcinoma and glioblastoma cell lines and was thought to inhibit metastasis by delaying the departure of tumor cells from the primary tumor [93]. The gene discussed is NRP2; the disease is breast carcinoma.